Timing of Assessment of Humoral and Cell-Mediated Immunity after Influenza Vaccination.

cellular immunity hemagglutination inhibition humoral immunity influenza vaccination interferon-gamma (IFN-γ) neutralizing antibody

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
27 May 2024
Historique:
received: 06 05 2024
revised: 24 05 2024
accepted: 26 05 2024
medline: 27 6 2024
pubmed: 27 6 2024
entrez: 27 6 2024
Statut: epublish

Résumé

Assessment of the immune response to influenza vaccines should include an assessment of both humoral and cell-mediated immunity. However, there is a lack of consensus regarding the timing of immunological assessment of humoral and cell-mediated immunity after vaccination. Therefore, we investigated the timing of immunological assessments after vaccination using markers of humoral and cell-mediated immunity. In the 2018/2019 influenza season, blood was collected from 29 healthy adults before and after vaccination with a quadrivalent inactivated influenza vaccine, and we performed serial measurements of humoral immunity (hemagglutination inhibition [HAI] and neutralizing antibody [NT]) and cell-mediated immunity (interferon-gamma [IFN-γ]). The HAI and NT titers before and after vaccination were strongly correlated, but no correlation was observed between the markers of cell-mediated and humoral immunity. The geometric mean titer and geometric mean concentration of humoral and cellular immune markers increased within 2 weeks after vaccination and had already declined by 8 weeks. This study suggests that the optimal time to assess the immune response is 2 weeks after vaccination. Appropriately timed immunological assessments can help ensure that vaccination is effective.

Identifiants

pubmed: 38932313
pii: vaccines12060584
doi: 10.3390/vaccines12060584
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : the Japan Society for the Promotion of Science KAKENHI
ID : 20K10458
Organisme : Hyogo Medical University Grant for Research Promotion
ID : 2023

Auteurs

Naruhito Otani (N)

Department of Public Health, Hyogo Medical University, Nishinomiya 663-8501, Hyogo, Japan.
Department of Infection Control and Prevention, Hyogo Medical University, Nishinomiya 663-8501, Hyogo, Japan.

Kazuhiko Nakajima (K)

Department of Infection Control and Prevention, Hyogo Medical University, Nishinomiya 663-8501, Hyogo, Japan.

Kumiko Yamada (K)

Department of Infection Control and Prevention, Hyogo Medical University, Nishinomiya 663-8501, Hyogo, Japan.

Kaori Ishikawa (K)

Department of Infection Control and Prevention, Hyogo Medical University, Nishinomiya 663-8501, Hyogo, Japan.

Kaoru Ichiki (K)

Department of Infection Control and Prevention, Hyogo Medical University, Nishinomiya 663-8501, Hyogo, Japan.

Takashi Ueda (T)

Department of Infection Control and Prevention, Hyogo Medical University, Nishinomiya 663-8501, Hyogo, Japan.

Yoshio Takesue (Y)

Department of Infection Control and Prevention, Hyogo Medical University, Nishinomiya 663-8501, Hyogo, Japan.

Takuma Yamamoto (T)

Department of Legal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Hyogo, Japan.

Satoshi Higasa (S)

Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya 663-8501, Hyogo, Japan.

Susumu Tanimura (S)

Department of Public Health Nursing, Mie University Graduate School of Medicine, Tsu 514-0001, Mie, Japan.

Yuta Inai (Y)

The Research Foundation for Microbial Diseases of Osaka University, Kanonji 768-0065, Kagawa, Japan.

Toshiomi Okuno (T)

Department of Microbiology, Hyogo Medical University, Nishinomiya 663-8501, Hyogo, Japan.

Classifications MeSH